Cargando…
Recombinant human thrombopoietin improved platelet engraftment after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
BACKGROUND: To evaluate the efficacy and safety of recombinant human thrombopoietin (rhTPO) for hematopoietic reconstitution after autologous stem cell transplant (ASCT) in patients with newly diagnosed multiple myeloma (NDMM). METHOD: Thirty‐five cases with NDMM had been enrolled into a prospective...
Autores principales: | Gu, Jingli, Liu, Junru, Li, Xiaozhe, Zou, Waiyi, Huang, Beihui, Chen, Meilan, Li, Juan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559510/ https://www.ncbi.nlm.nih.gov/pubmed/34569193 http://dx.doi.org/10.1002/cam4.4294 |
Ejemplares similares
-
Comparison of efficacy, safety, patients’ quality of life, and doctors’ occupational stress between lenalidomide‐based and bortezomib‐based induction in patients with newly diagnosed multiple myeloma
por: Xu, Limei, et al.
Publicado: (2021) -
Health‐related quality of life of patients with multiple myeloma: A real‐world study in China
por: Li, Xiaozhe, et al.
Publicado: (2020) -
Prognostic Significance of the Stage at Which an MRD-Negative Status Is Achieved for Patients With Multiple Myeloma Who Received ASCT
por: Sun, Qian, et al.
Publicado: (2022) -
Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study
por: Xiaozhe, Li, et al.
Publicado: (2022) -
1q21 Gain Combined with High‐Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China
por: Li, Xiaozhe, et al.
Publicado: (2019)